A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer
1996

Study on Cyclin D1 and p53 in Breast Cancer

Sample size: 248 publication Evidence: moderate

Author Information

Author(s): R Michalides, P Hageman, H van Tinteren, L Houben, E Wientjens, R Klompmaker, J Peterse

Primary Institution: The Netherlands Cancer Institute

Hypothesis

What is the pathological relevance of cyclin D1 overexpression in human breast cancer?

Conclusion

Overexpression of cyclin D1 and p53 was not found to be of prognostic value in operable breast cancer patients.

Supporting Evidence

  • Overexpression of cyclin D1 was found in 34% of breast cancer cases.
  • Overexpression of p53 was found in 18% of breast cancer cases.
  • Overexpression of cyclin D1 was associated with estrogen receptor-positive tumors.
  • Overexpression of p53 was associated with poorly differentiated tumor types.

Takeaway

This study looked at breast cancer patients to see if certain proteins, cyclin D1 and p53, could help predict how well they would do. It turns out, they didn't really help with that.

Methodology

The study involved immunohistochemical analysis of tumor samples from 248 patients with operable breast cancer, assessing the overexpression of cyclin D1 and p53.

Potential Biases

Potential bias due to the selection of patients who were operable and did not have distant metastasis.

Limitations

The study was limited to operable breast cancer patients and may not apply to more advanced cases.

Participant Demographics

Patients were treated at the Netherlands Cancer Institute between 1974 and 1982, with a median follow-up of 106 months.

Statistical Information

P-Value

0.049

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication